Stock Fundamentals

Company Information

▼
Company Name
Merus BV
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: NL0011606264
CIK: 0001651311
CUSIP: N5749R100
Currency: USD
Full Time Employees: 260
Phone: 31 30 253 8800
Website: https://www.merus.nl
Fiscal Year End: December
IPO Date: May 19, 2016
Description:

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.

Address:

Uppsalalaan 17, Utrecht, Netherlands, 3584 CT

Directors & Officers

▼
Name Title Year Born
Mr. Gregory D. Perry Chief Financial Officer 1960
Mr. Peter B. Silverman J.D. EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal 1978
Dr. Fabian Zohren M.D., Ph.D. Chief Medical Officer 1976
Dr. Jan G.J. van de Winkel Ph.D. CEO & Executive Director NA
Dr. Hennie Hoogenboom Co-Founder and Scientific Advisor NA
Mr. Harry Shuman Chief Accounting Officer NA
Mr. Cornelis Adriaan de Kruif Ph.D. CTO & Executive VP 1964
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. Chief Scientific Officer & Senior VP NA
Ms. Sherri Spear Senior Vice President of Investor Relations & Strategic Communications NA
Ms. Kathleen Farren Director of IR & Corporate Communications Officer NA

Institutional Holders

▼
Holder Name Shares Date Reported % Out Value % Change
FMR Inc 7.49M Jun 30, 2025 9.90% $0.02 7.51%
Paradigm Biocapital Advisors LP 4.28M Jun 30, 2025 5.66% $9.62 27.07%
RTW INVESTMENTS, LLC 4.00M Jun 30, 2025 5.29% $3.00 -4.05%
Wellington Management Company LLP 3.73M Jun 30, 2025 4.93% $0.04 -21.01%
COMMODORE CAPITAL LP 3.53M Jun 30, 2025 4.66% $13.09 -21.19%
Deerfield Management Co 3.38M Jun 30, 2025 4.48% $3.23 6.64%
venBio Select Advisor LLC 3.16M Jun 30, 2025 4.17% $2.91 5.19%
T. Rowe Price Associates, Inc. 2.26M Jun 30, 2025 2.99% $0.01 106.44%
Holocene Advisors, LP 2.23M Jun 30, 2025 2.94% $0.29 18.77%
Westfield Capital Management Company, L.P. 2.04M Jun 30, 2025 2.70% $0.45 36.05%
Franklin Resources Inc 1.84M Jun 30, 2025 2.43% $0.03 -7.71%
Polar Capital Holdings PLC 1.61M Jun 30, 2025 2.13% $0.44 -5.61%
Woodline Partners LP 1.54M Jun 30, 2025 2.04% $0.43 10.19%
Federated Hermes Inc 1.53M Jun 30, 2025 2.02% $0.15 46.33%
Driehaus Capital Management LLC 1.37M Jun 30, 2025 1.81% $0.58 8.94%
Ameriprise Financial Inc 1.13M Jun 30, 2025 1.50% $0.01 1,007.28%
Cormorant Asset Management, LLC 1.12M Jun 30, 2025 1.48% $4.39 51.35%
AllianceBernstein L.P. 1.10M Jun 30, 2025 1.46% $0.02 49.11%
Rock Springs Capital Management LP 1.06M Jun 30, 2025 1.41% $3.49 8.45%
BlackRock Inc 1.05M Jun 30, 2025 1.39% $0.00 -37.88%

Shares Statistics

▼
Shares Outstanding: 75.85M
Shares Float: 70.01M
% Insiders: 9,704.50%
% Institutions: 9,280.20%
Short % Float: 1.08%

🏆 Top 10 Institutional Holders

▼
Rank Holder Name Shares Held % of Shares Change Date Reported
1 FMR Inc 7.49M 9.90% ▲ 7.51% Jun 30, 2025
2 Paradigm Biocapital Advisors LP 4.28M 5.66% ▲ 27.07% Jun 30, 2025
3 RTW INVESTMENTS, LLC 4.00M 5.29% ▼ 4.05% Jun 30, 2025
4 Wellington Management Company LLP 3.73M 4.93% ▼ 21.01% Jun 30, 2025
5 COMMODORE CAPITAL LP 3.53M 4.66% ▼ 21.19% Jun 30, 2025
6 Deerfield Management Co 3.38M 4.48% ▲ 6.64% Jun 30, 2025
7 venBio Select Advisor LLC 3.16M 4.17% ▲ 5.19% Jun 30, 2025
8 T. Rowe Price Associates, Inc. 2.26M 2.99% ▲ 106.44% Jun 30, 2025
9 Holocene Advisors, LP 2.23M 2.94% ▲ 18.77% Jun 30, 2025
10 Westfield Capital Management Company, L.P. 2.04M 2.70% ▲ 36.05% Jun 30, 2025

Valuation Metrics

▼
Enterprise Value: $6.20B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $6.83B
EBITDA: $-368.77M
PEG Ratio: $0.00
Book Value: $10.22
Earnings/Share: $-5.28
Profit Margin: 0.00%
Operating Margin: -794.06%
ROA (TTM): -26.53%
ROE (TTM): -51.57%
Revenue (TTM): $56.61M
Revenue/Share (TTM): $0.80
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 3.20%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Download Financials (Excel)

Financial Charts

▼

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

▼

Financial Ratios (Yearly)

▼

Financial Ratios (Quarterly)

▼

Earnings History

▼

Balance Sheet (Yearly)

▼

Financial Ratios

▼
Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2024-12-31 6.54x 0.00x 0.17x -8.53x -0.01x
2023-12-31 5.34x 0.00x 0.22x -9.77x -0.01x
2022-12-31 3.88x 0.01x 0.34x -54.91x -0.01x
2021-12-31 5.90x 0.00x 0.31x -612.81x -0.02x
2020-12-31 4.66x 0.01x 0.56x -3.35x -0.02x
2019-12-31 6.72x 0.01x 0.50x -8.10x -0.03x
2018-12-31 6.75x 0.00x 0.58x -8,726.50x -0.01x
2017-12-31 10.05x 0.17x 0.76x -154.87x -0.29x
2016-12-31 9.17x 0.01x 0.53x -1.35x -0.02x
2015-12-31 5.46x 0.02x 0.20x -108.40x -0.04x
2014-12-31 0.46x -0.23x 2.01x -367.32x -0.08x
2013-12-31 2.91x 0.10x 0.38x -130.43x -0.11x
2012-12-31 4.58x 0.03x 0.31x N/A N/A

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 29, 2025 A/S Genmab N/A Purchase 1.05M $97.00 $102.12M
Dec 26, 2025 A/S Genmab N/A Purchase 142.61K $97.00 $13.83M
Dec 26, 2025 A/S Genmab N/A Purchase 2.98K $97.00 $288.87K
Dec 24, 2025 A/S Genmab N/A Purchase 96.08K $97.00 $9.32M
Dec 23, 2025 A/S Genmab N/A Purchase 561.04K $97.00 $54.42M
Dec 22, 2025 A/S Genmab N/A Purchase 15.71K $97.00 $1.52M
Dec 19, 2025 A/S Genmab N/A Purchase 66.26K $97.00 $6.43M
Dec 18, 2025 A/S Genmab N/A Purchase 212.18K $97.00 $20.58M
Dec 17, 2025 A/S Genmab N/A Purchase 150.80K $97.00 $14.63M
Dec 16, 2025 A/S Genmab N/A Purchase 120.75K $97.00 $11.71M
Nov 26, 2025 Harry Shuman N/A Sale 1.70K $96.10 $163.37K
Nov 25, 2025 Harry Shuman N/A Sale 8.30K $95.92 $796.14K
Jul 17, 2025 Peter B. Silverman N/A Sale 25.00K $60.00 $1.50M
Jul 10, 2025 Peter B. Silverman N/A Sale 16.81K $55.00 $924.28K
Jul 09, 2025 Peter B. Silverman N/A Sale 6.70K $55.00 $368.23K
Jun 20, 2025 Peter B. Silverman N/A Sale 34.00K $52.76 $1.79M

📦 Raw API Data (JSON Explorer)

▼

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about MRUS.US!